ArticleNature ecology & evolution2024
A large-scale in silico replication of ecological and evolutionary studies.
Article in Nature ecology & evolution, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- AI-empowered human microbiome research.Gut · 2026Review
- Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysis.European journal of cancer (Oxford, England : 1990) · 2025Article
- Let's DAG in: how directed acyclic graphs can help behavioural ecology be more transparent.Proceedings. Biological sciences · 2025Article
- A large-scale in silico replication of ecological and evolutionary studies.Nature ecology & evolution · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite the growing concerns about the replicability of ecological and evolutionary studies, no results exist from a field-wide replication project. We conduct a large-scale in silico replication project, leveraging cutting-edge statistical methodologies. Replicability is 30%-40% for studies with marginal statistical significance in the absence of selective reporting, whereas the replicability of studies presenting 'strong' evidence against the null hypothesis H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.